tradingkey.logo

Intelligent Bio Solutions Inc

INBS

1.491USD

+0.021+1.41%
Market hours ETQuotes delayed by 15 min
10.13MMarket Cap
LossP/E TTM

Intelligent Bio Solutions Inc

1.491

+0.021+1.41%
More Details of Intelligent Bio Solutions Inc Company
Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
Company Info
Ticker SymbolINBS
Company nameIntelligent Bio Solutions Inc
IPO dateDec 23, 2020
CEOMr. Harry Simeonidis
Number of employees13
Security typeOrdinary Share
Fiscal year-endDec 23
Address135 W 41St St,
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10036
Phone16467905756
Websitehttps://ibs.inc/
Ticker SymbolINBS
IPO dateDec 23, 2020
CEOMr. Harry Simeonidis
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Harry Simeonidis
Mr. Harry Simeonidis
President, Chief Executive Officer
President, Chief Executive Officer
40.41K
+0.15%
Mr. Jonathan S. Hurd
Mr. Jonathan S. Hurd
Independent Director
Independent Director
63.00
--
Mr. Valter Pinto
Mr. Valter Pinto
Managing Director
Managing Director
--
--
Dr. Steven Boyages, Ph.D.
Dr. Steven Boyages, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Spiro Sakiris
Mr. Spiro Sakiris
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nicola Fraser
Ms. Nicola Fraser
Independent Director
Independent Director
--
--
Mr. Jason Isenberg
Mr. Jason Isenberg
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Harry Simeonidis
Mr. Harry Simeonidis
President, Chief Executive Officer
President, Chief Executive Officer
40.41K
+0.15%
Mr. Jonathan S. Hurd
Mr. Jonathan S. Hurd
Independent Director
Independent Director
63.00
--
Mr. Valter Pinto
Mr. Valter Pinto
Managing Director
Managing Director
--
--
Dr. Steven Boyages, Ph.D.
Dr. Steven Boyages, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Spiro Sakiris
Mr. Spiro Sakiris
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Nicola Fraser
Ms. Nicola Fraser
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
No Data
By RegionUSD
Name
Revenue
Proportion
United Kingdom
692.16K
94.96%
Other
31.43K
4.31%
Australia
5.28K
0.72%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 9
Updated: Wed, Jul 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alyeska Investment Group, L.P.
8.26%
Altium Capital Management LP
2.01%
Sakiris (Spiro Kevin)
0.73%
Geode Capital Management, L.L.C.
0.66%
Simeonidis (Harry)
0.54%
Other
87.81%
Shareholders
Shareholders
Proportion
Alyeska Investment Group, L.P.
8.26%
Altium Capital Management LP
2.01%
Sakiris (Spiro Kevin)
0.73%
Geode Capital Management, L.L.C.
0.66%
Simeonidis (Harry)
0.54%
Other
87.81%
Shareholder Types
Shareholders
Proportion
Hedge Fund
8.26%
Investment Advisor/Hedge Fund
2.67%
Individual Investor
1.27%
Investment Advisor
0.73%
Research Firm
0.17%
Venture Capital
0.13%
Other
86.77%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
34
983.63K
13.23%
+463.06K
2025Q1
36
981.28K
14.20%
+429.65K
2024Q4
38
214.35K
3.16%
-507.92K
2024Q3
38
390.00K
7.80%
-236.97K
2024Q2
42
449.42K
76.55%
-259.12K
2024Q1
46
732.30K
88.07%
+589.21K
2023Q4
40
172.56K
98.30%
+79.74K
2023Q3
42
49.64K
11.24%
+14.21K
2023Q2
43
60.27K
19.45%
+30.17K
2023Q1
42
45.22K
32.24%
+33.92K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Alyeska Investment Group, L.P.
613.89K
8.88%
+613.89K
--
Mar 31, 2025
Altium Capital Management LP
149.25K
2.16%
+149.25K
--
Mar 31, 2025
Sakiris (Spiro Kevin)
53.93K
0.78%
+171.00
+0.32%
Mar 18, 2025
Geode Capital Management, L.L.C.
49.01K
0.71%
+22.41K
+84.25%
Mar 31, 2025
Simeonidis (Harry)
40.41K
0.58%
+59.00
+0.15%
Mar 18, 2025
Susquehanna International Group, LLP
35.49K
0.51%
+35.49K
--
Mar 31, 2025
The Vanguard Group, Inc.
15.48K
0.22%
--
--
Mar 31, 2025
Goldman Sachs & Company, Inc.
12.82K
0.19%
+12.82K
--
Mar 31, 2025
Ionic Ventures LLC
9.40K
0.14%
+9.40K
--
Dec 31, 2023
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Feb 09, 2023
Merger
20<1
Feb 09, 2023
Merger
20<1
Date
Type
Ratio
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Jan 25, 2024
Merger
12<1
Feb 09, 2023
Merger
20<1
Feb 09, 2023
Merger
20<1
Feb 09, 2023
Merger
20<1
Feb 09, 2023
Merger
20<1
KeyAI